Atlas Trials

A Multicenter Randomized Phase III Study Comparing Second-line Treatment With Chemotherapy Associated or Not to Erlotinib in NSCLC Patients With Secondary Resistance to TKI-EGFR

Clinical trial NCT02178397 · TERMINATED

Trial details

NCT number
NCT02178397
Sponsor
Centre Francois Baclesse
Status
TERMINATED
Phase
Phase 3
Study type
INTERVENTIONAL
NSCLC Patients With EGFR Activating Mutation
Start date
2014-06-01
Primary completion
2015-09-01
Enrollment
6

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.